To date, there are only 3 FDA-approved tests with clinical utility in NSCLC patients, namely Cobas® EGFR Mutation Test v2 (Roche Molecular Systems, Inc., Pleasanton, CA, USA), Guardant360® CDx test (Guardant Health, Inc., Redwood City, CA, USA), and The FoundationOne Liquid® CDx test (Foundation Medicine, Inc., Cambridge, MA, USA). This evidence concerns the gene EGFR and non-small cell lung carcinoma.